Adial Pharmaceuticals' Potential Treatment For Alcohol Use Disorder Shows Encouraging Safety, Patient Compliance
Wednesday, Adial Pharmaceuticals Inc ADIL announced the publication of a peer-reviewed article highlighting the clinical results, strong safety profile, and high compliance among patients administered AD04 (low-dose ondansetron). AD04 is the company’s lead investigational new drug product being…#alcoholusedisorder #aud #phase3 #alt #ast #serumbilirubin #adialpharmaceuticals #adial (Source: Reuters: Health)
Source: Reuters: Health - April 10, 2024 Category: Consumer Health News Source Type: news
TikTok Influencers Are Now Treating Ozempic Side Effects
Every day dozens of people come to Jennifer Witherspoon—a former dental office manager with zero medical training—for help managing nausea, headaches, and other side effects that can come with taking weight-loss shots. She even crafted a template response to help her quickly get through the messages.
“People have offered to pay me, begged me to start a podcast, asked me to call their sisters-in-law, wanted me to call their doctor,” she said. “One lady even invited me to her wedding.” Even Oprah’s production company reached out to feature one of her videos in a prime time specia...
Source: TIME: Health - March 7, 2024 Category: Consumer Health News Authors: Madison Muller, Andre Tartar, and Tanaz Meghjani/Bloomberg Tags: Uncategorized healthscienceclimate wire Source Type: news
The effect of cannabis use on depression - Hutchinson J, Sall S, Stevens L.
This article presents the case of a 21-year-old female with a psychiatric history of depression and a history of chronic cannabis use who presented to the emergency department after overdosing on ondansetron and was urine test positive for marijuana (tetra... (Source: SafetyLit)
Source: SafetyLit - February 9, 2024 Category: International Medicine & Public Health Tags: Alcohol and Other Drugs Source Type: news
Ondansetron for Irritable Bowel Syndrome With Diarrhea Ondansetron for Irritable Bowel Syndrome With Diarrhea
This placebo-controlled RCT demonstrated the efficacy of titrated ondansetron for managing key symptoms of IBS-D.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - June 15, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
US Appeals Court Won't Revive Zofran Cases Against GSK US Appeals Court Won't Revive Zofran Cases Against GSK
A federal appeals court declined to revive hundreds of lawsuits by women who claim that GlaxoSmithKline failed to warn them that taking the anti-nausea drug Zofran during pregnancy could cause birth defects.Reuters Health Information (Source: Medscape Medical News Headlines)
Source: Medscape Medical News Headlines - January 10, 2023 Category: Consumer Health News Tags: Ob/Gyn & Women ' s Health News Source Type: news
9 Wellness Trends to Ditch in 2023
In 2022, social media inspired many of the ways we tried to get and stay healthy—but not always for the better. Weight-loss drugs spread like wildfire online, as did our collective agreement to stop going the extra mile at work. We turned to Dr. TikTok again and again, and focused perhaps too much on body image—even when we tried to keep things positive.
The new year is the perfect time to re-evaluate these habits, experts say. Here are nine wellness trends you’d be better off ditching in 2023—plus healthier alternatives.
Weight-loss shots
Ozempic and Wegovy, two weight-loss injections that are used...
Source: TIME: Health - December 12, 2022 Category: Consumer Health News Tags: Uncategorized healthscienceclimate Research Wellbeing Source Type: news
Oncologists Frustrated Over Limits on Low-Cost Antiemetics Oncologists Frustrated Over Limits on Low-Cost Antiemetics
Current limits on low-cost generic antiemetics, allowing for example only nine ondansetron tablets each month, are leading to needless suffering and, ultimately, extra cost.Medscape Medical News (Source: Medscape Hematology-Oncology Headlines)
Source: Medscape Hematology-Oncology Headlines - May 26, 2022 Category: Cancer & Oncology Tags: Hematology-Oncology News Source Type: news
What About This?: Ondansetron Can Treat Migraine (Yes, Ondansetron)
No abstract available (Source: Emergency Medicine News)
Source: Emergency Medicine News - April 1, 2022 Category: Emergency Medicine Tags: What About This? Source Type: news
ondansetron
Title: ondansetronCategory: MedicationsCreated: 3/18/2022 12:00:00 AMLast Editorial Review: 3/18/2022 12:00:00 AM (Source: MedicineNet Digestion General)
Source: MedicineNet Digestion General - March 18, 2022 Category: Nutrition Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Nueva informaci ón sobre la prolongación del intervalo QT con ondansetrón (Zofran)
El 29 de julio, La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) está informando a los profesionales de la salud y al público que los resultados preliminares de recientes pruebas clínicas indican que una sola dosis intravenosa de 32 mg de ondansetrón (Zofran, hidrocloruro de ond ansetrón y genéricos) puede alterar la actividad eléctrica del corazón (prolongación del intervalo QT), lo cual puede predisponer a los pacientes a producir un ritmo cardiaco anormal y potencialmente mortal conocido como Torsade de Pointes. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - February 9, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
Oral Mosapride as Anti-emetic Following General Anesthesia Oral Mosapride as Anti-emetic Following General Anesthesia
Might the addition of prophylactic oral mosapride to a protocol including dexamethasone and ondansetron further reduce postoperative nausea and vomiting after general anesthesia?BMC Anesthesiology (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - February 2, 2021 Category: Consumer Health News Tags: Anesthesiology Journal Article Source Type: news
Comunicado de la FDA sobre la seguridad de los medicamentos: Informaci ón actualizada sobre la dosis intravenosa de 32 mg de ondansetrón (Zofran) y productos previamente mezclados de ondansetrón
[12-5-12] La Administraci ón de Alimentos y Medicamentos de Estados Unidos (FDA por sus siglas en inglés) notificó a los profesionales de la salud que ya no se comercializará la dosis intravenosa de 32 mg de Zofran (hidrocloruro de ondansetrón), un medicamento para prevenir las náuseas, debido al potencial de serios ri esgos para el corazón (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 26, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
FDA Drug Safety Communication: New information regarding QT prolongation with ondansetron (Zofran)
The U.S. Food and Drug Administration (FDA) is informing healthcare professionals and the public that preliminary results from a recently completed clinical study suggest that a 32 mg single intravenous dose of ondansetron (Zofran, ondansetron hydrochloride, and generics) may affect the electrical activity of the heart (QT interval prolongation), which could pre-dispose patients to develop an abnormal and potentially fatal heart rhythm known as Torsades de Pointes. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - January 8, 2021 Category: Drugs & Pharmacology Authors: FDA Source Type: news
How a 65p pill can end the terrifying delusions that haunt thousands with Parkinson's
A ground-breaking NHS trial will start next month, offering 200 volunteers the chance to try a drug called ondansetron which has been shown in studies to help halt hallucinations. (Source: the Mail online | Health)
Source: the Mail online | Health - October 24, 2020 Category: Consumer Health News Source Type: news
Featured Review: Drugs for preventing postoperative nausea and vomiting in adults after general anaesthesia: a network meta-analysis
ConclusionsFor people at higher risk, some medicines worked well to stop them from being sick after general anaesthesia. The most reliable antiemetic medicines were aprepitant, ramosetron, granisetron, dexamethasone, and ondansetron, followed by fosaprepitant and droperidol.However, the authors did not find enough reliable evidence about potential unwanted effects to rank these medicines reliably according to how well they worked.Read the full review on the Cochrane LibraryVisit the Cochrane Anaesthesia Group websiteTuesday, October 20, 2020 (Source: Cochrane News and Events)
Source: Cochrane News and Events - October 15, 2020 Category: Information Technology Authors: Rachel Klabunde Source Type: news
